Verily Life Sciences

Syllable is a platform for building AI agents, managing AI operations, tools integrations and third party providers of LLMs and AI services.

EQRx operates as a biotechnology company, focused on re-engineering the process from drug discovery to patient delivery with the goal of offering a market-based solution for the rising cost of medicines. By bringing together stakeholders from across the healthcare system and utilizing the latest advances in science and technology, the company seeks to discover, develop and deliver high-quality, patent-protected medicines more efficiently and cost-effectively than ever before. The company was founded in 2019 and is based in Cambridge, Massachusetts, United States.

Culture Biosciences develops automated bio-reactor that helps biotech companies optimize their manufacturing processes and brings products to market faster. The company also builds automated tools for fermentation. It has a digital bio-manufacturing platform to enable scientists to run, monitor, and analyze bio-reactors faster than traditional approaches by robotic sample handling and cloud data monitoring and analysis. Culture Biosciences was founded in 2016 and is headquartered in San Francisco, California.

Genalyte, Inc. is a life sciences company developing and commercializing innovative next-generation multiplexing technology. Genalyte has developed a new approach to immunodetection using silicon chip manufacturing methods. Its Maverick platform uses a technology called silicon photonics to directly measure protein binding between antibodies and antigens or hybridization of nucleic acids.

Culture Biosciences develops automated bio-reactor that helps biotech companies optimize their manufacturing processes and brings products to market faster. The company also builds automated tools for fermentation. It has a digital bio-manufacturing platform to enable scientists to run, monitor, and analyze bio-reactors faster than traditional approaches by robotic sample handling and cloud data monitoring and analysis. Culture Biosciences was founded in 2016 and is headquartered in San Francisco, California.

Mammoth Biosciences is harnessing the diversity of nature to power the next-generation of CRISPR products. Through the discovery and development of novel CRISPR systems, the company is enabling the full potential of its platform to read and write the code of life. Mammoth Biosciences aims to democratize disease detection with an easy and affordable point-of-care test that allows real-time and simultaneous detection of multiple conditions. By leveraging its internal research and development and exclusive licensing to Cas12, Cas13, and Cas14, Mammoth Biosciences can provide enhanced diagnostics and genome editing for life science research, healthcare, agriculture, biodefense and more. Based in South San Francisco, Mammoth Biosciences is co-founded by CRISPR pioneer Jennifer Doudna and principal founders Trevor Martin, Janice Chen, and Lucas Harrington. The firm is backed by top institutional investors including Mayfield, NFX, and 8VC, Decheng Capital and leading individual investors including Brook Byers, Tim Cook, and Jeff Huber. Mammoth has also been working on developing a rapid COVID-19 test.

Freenome is a biotech company developing accurate, accessible, and non-invasive disease screening products for proactively treating cancer and other diseases at their most manageable stages. The company is developing a simple blood test to detect early-stage cancer and make treatments more effective and provides a platform that helps design healthy conditions for an individual based on his/her cell-free genome. The company aims to reinvent disease management through systematized early detection and intervention.

Culture Biosciences develops automated bio-reactor that helps biotech companies optimize their manufacturing processes and brings products to market faster. The company also builds automated tools for fermentation. It has a digital bio-manufacturing platform to enable scientists to run, monitor, and analyze bio-reactors faster than traditional approaches by robotic sample handling and cloud data monitoring and analysis. Culture Biosciences was founded in 2016 and is headquartered in San Francisco, California.

Ciitizen’s mission is to provide Earth’s 7.3 billion citizens with control of their complete health information and give them the choice of sharing it with whomever they want. Period. With this new ownership, patients can share their health history with caregivers, share for second opinions, and with companies/researchers who may hold the answer to their treatment. All patients have a right to all of their health information, yet existing portals pull only minimal clinical information from a fraction of health care institutions. Current “interoperability” initiatives leave the patient out of the picture and often rely on armies of manual labor to extract key health insights from unstructured textual data—an expensive model which doesn’t scale. In the near future, citizens will walk into a clinical facility and, with a simple tap of a mobile device, release their health information to themselves, where Ciitizen normalizes unstructured data from across the healthcare ecosystem into actionable visualizations for patients, their caregivers, and clinicians. Ciitizen has assembled an all-star team, led by its CEO, Anil Sethi (last company was sold to Apple) and is backed by a strong investment team led by Andreessen Horowitz, Verily, Section 32 and others.

Oscar is a health insurance company that offers individual and family plans, medicare advantages, and small group products. It employs technology, design, and data to humanize health care. The company offers plans to individuals, couples, and families living in parts of New York, New Jersey, California, and Texas who don’t receive health insurance from an employer. In 2012, Joshua Kushner, Kevin Nazemi, and Mario Schlosser headquartered Oscar Health in New York, New York.

Onduo is a digital healthcare company that uses data to help people with chronic conditions (hypertension and T2D) live their best life.